A new analysis of two clinical trials in Europe and the United States provides evidence that prostate-specific antigen (PSA) screening reduces prostate cancer mortality. The study published in Annals of Internal Medicine, found that screening lowered the risk for prostate cancer death by 25 to 32 percent in men when compared with those who were not screened.

 

Contact:         Wendy Poage

President, Prostate Conditions Education Council

(303) 316-4685

This email address is being protected from spambots. You need JavaScript enabled to view it.

 

For Immediate Release
September 5, 2017

Study finds screening linked to reduced risk for prostate cancer death

Prostate Conditions Education Council supports clearer review of clinical trials; kicks off Prostate Cancer Awareness Month efforts with programs, free screenings

DENVER – A new analysis of two clinical trials in Europe and the United States provides evidence that prostate-specific antigen (PSA) screening reduces prostate cancer mortality. The study, published in Annals of Internal Medicine, found that screening lowered the risk for prostate cancer death by 25 to 32 percent in men when compared with those who were not screened.

The Prostate Conditions Education Council (PCEC) strongly supports this analysis, which is timely in light of expected updates to prostate cancer screening recommendations from the U.S. Preventive Services Task Force (USPSTF). September is also Prostate Cancer Awareness Month, which the PCEC recognizes with educational programs and free prostate testing across the U.S. and in Japan. The organization has tested more than five million men for prostate cancer during the past 30 years.

“The past few years posed an opportunity for the PCEC to forge ahead and refine efforts to make sure patients understand that PSA screening isn’t a cancer diagnosis – it helps them and their providers make informed decisions,” said Wendy Poage, president of the PCEC. “Screening helps save lives, and this analysis only bolsters the work we do to provide information and support for men and their loved ones.”

The new analysis, funded by the National Cancer Institute, assessed the differences between the European Randomized Study of Screening for Prostate Cancer (ERSPC) and the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO). In past reviews, interpretation was complicated by differences in practice settings and trial implementation.

“When we accounted for the actual amount of screening received, the two trials have remarkably similar results,” said E. David Crawford, M.D., a co-author of the study and founder and chairman of the PCEC. “Instead of comparing the screened and non-screened populations, we looked at the intensity of screening in each relative to no screening. The estimated common effect of screening suggests it can significantly reduce the risk for prostate cancer death.”

As the USPSTF works to update its recommendations, the PCEC urges the inclusion of this new evidence in materials considered during the task force’s review. Prostate cancer remains the second-leading cause of cancer death among men in the U.S. and is most successfully treated when detected in its early stages.

About the Prostate Conditions Education Council

A national organization committed to men’s health, the PCEC is the nation’s leading resource for information on prostate health. The PCEC is dedicated to saving lives through awareness and the education of men, the women in their lives and the medical community about prostate cancer prevalence, the importance of early detection and available treatment options, as well as other men’s health issues. The Council, comprised of a consortium of leading physicians, health educators, scientists and prostate cancer advocates, aims to conduct nationwide screenings for men and perform research that will aid in the detection and treatment of prostate conditions. More information is available at prostateconditions.org.

###

 

Prostate cancer is a disease that is most successfully treated when it is detected early on.  As the research community explores various methods to detecting the disease, PCEC continues to encourage men to play an active role in their health by looking to those trusted sources of prostate cancer testing – the PSA and DRE.

~Dr. E. David Crawford
Head of the Urologic Oncology Department at the University of Colorado Health Sciences Center
Founder/Chairman of PCEC

Join Our Newsletter